FDA Accepts Cytokinetics' Application for Cardiovascular Drug [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
has assigned a standard review with a target action date of September 26, 2025. (Source: Cytokinetics' announcement) The study showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, with statistically significant improvements in all 10 prespecified secondary endpoints. (Source: Cytokinetics' announcement) A potential approval and successful development of aficamten will be a significant boost for Cytokinetics, as it currently does not have any approved product in its portfolio. (Source: Zacks Investment Research) Bayer AG will acquire rights to aficamten in Japan and plans to conduct a phase III study in Japanese patients with obstructive HCM, while Cytokinetics will expand its ongoing studies, ACACIA-HCM and CEDAR-HCM, into Japan. (Source: Cytokinetics' announcement) Cytokinetics will receive an upfront payment of €50 million, an additional €90 million upon achieving milestones through commercial launch, and up to €490
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyGlobeNewswire
- Why Cytokinetics Stock Was a Nearly 5% Winner Today [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- CYTK's page on the SEC website